Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07305805
PHASE1

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The purpose of this clinical study is to find out how the novel insulin NNC0363-1063 and a non-glucose carbohydrate used in food and beverage might interact in participants with type 1 diabetes and if co-administration of these substances is safe and tolerable. All participants will get a fixed dose of NNC0363-1063 and an oral administration of different amounts of the non-glucose carbohydrate in a random order during 4 interaction tests. The participants will be in this clinical study for about 5 to 12 weeks.

Official title: A Multiple Dose Study Investigating Pharmacodynamics and Pharmacokinetics of Subcutaneous NNC0363-1063 in Participants With Type 1 Diabetes

Key Details

Gender

All

Age Range

18 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2025-12-15

Completion Date

2026-05-21

Last Updated

2026-01-02

Healthy Volunteers

No

Interventions

DRUG

NNC0363-1063

NNC0363-1063 will be administered subcutaneously.

Locations (1)

Profil Institut für Stoffwechselforschung GmbH

Neuss, Germany